title: Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
abstract: BACKGROUND
  Data on the effectiveness of biologics in the treatment of nail and scalp psoriasis (PSO) in a routine clinical setting are scarce. The aim of this study was therefore to evaluate the effectiveness of adalimumab in the treatment of nail and scalp psoriatic lesions in routine dermatologic practice.
  
  
  METHODS
  Five hundred one patients were analyzed in this observational study; 157 patients had nail involvement (nail PSO set; NPS) and 404 had scalp involvement (scalp PSO set; SPS). Patients treated with adalimumab were observed for up to 12 months. Outcomes were evaluated via changes in the Nail Psoriasis Severity Index (NAPSI), Psoriasis Scalp Severity Index (PSSI), Psoriasis Area and Severity Index (PASI), and QoL (using the Dermatology Life Quality Index).
  
  
  RESULTS
  Eighty-four percent of the patients in the NPS and 93.8% in the SPS achieved a good clinical response upon treatment with adalimumab. Complete clearing of local symptoms was achieved by 33.3% of the patients with nail involvement and 66.7% of the patients with scalp involvement. There was also a marked improvement in QoL.
  
  
  CONCLUSIONS
  Adalimumab appears to be an effective treatment for scalp and nail PSO in patients with moderate to severe plaque PSO. No new clinical concerns were established.
authors.affiliation: Institute of Psoriasis and Chronic Dermatoses, Kyiv, Ukraine.
authors.forename: Kuzma
authors.initials: K
authors.lastname: Khobzey
authors.affiliation: Medical Department, AbbVie Biopharmaceuticals GmbHKyiv, Ukraine.
authors.forename: Iryna
authors.initials: I
authors.lastname: Liskova
authors.affiliation: Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
authors.forename: Andrea
authors.initials: A
authors.lastname: Szegedi
authors.affiliation: Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
authors.forename: Lev
authors.initials: L
authors.lastname: Pavlovsky
authors.affiliation: Department of Dermatovenereology, University Medical Centre Ljubljana, Slovenia and Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
authors.forename: Tomaž
authors.initials: T
authors.lastname: Lunder
authors.affiliation: Dermatology Clinic, Tartu University HospitalTartu, Estonia.
authors.forename: Külli
authors.initials: K
authors.lastname: Kingo
authors.affiliation: Department of Dermatovenerology, University Medical CenterMaribor, Slovenia.
authors.forename: Jovan
authors.initials: J
authors.lastname: Miljković
authors.affiliation: Department of Dermatovenereology, University Hospital in Martin, Jessenius Faculty of Medicine in Martin of Comenius University, Bratislava, Slovakia.
authors.forename: Juraj
authors.initials: J
authors.lastname: Péč
authors.affiliation: Medical Department, AbbVie d.o.o., Ljubljana, Slovenia.
authors.forename: Maša
authors.initials: M
authors.lastname: Bohinc
authors.affiliation: Global Medical Affairs Immunology, AbbVie, Ljubljana, Slovenia.
authors.forename: Maja
authors.initials: M
authors.lastname: Hojnik
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000188:drug therapy*; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D012536:Scalp Dermatoses / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab